About 53 results

ALLMedicine™ Acquired Pure Red Cell Aplasia Center

Research & Reviews  20 results

A 46-Year-Old Thai Woman with Secondary Acquired Pure Red Cell Aplasia Due to Treatment...
The American Journal of Case Reports; Kitpermkiat R, Thotsiri S et. al.

Jul 18th, 2022 - BACKGROUND Pure red cell aplasia (PRCA) is an uncommon cause of anemia in end-stage kidney disease (ESKD). It is attributed to recombinant human erythropoietin (rHuEPO) administration. Although immunosuppression is the mainstay therapy, its effect...

Incidence of Acquired Pure Red Cell Aplasia: A Nationwide Epidemiologic Analysis With 2...
Blood Advances; Nakazawa H, Sakai K et. al.

May 7th, 2022 - Acquired pure red cell aplasia (PRCA) is a rare syndrome characterized by anemia with reticulocytopenia and a marked reduction in erythroid precursors. Given its rarity, the true incidence is largely unknown, and epidemiological data representing ...

Sirolimus is effective for refractory/relapsed/intolerant acquired pure red cell aplasi...
Leukemia Huang Y, Chen M et. al.

Mar 9th, 2022 - Some patients with acquired pure red cell aplasia (aPRCA) have no response or are intolerant to cyclosporine A. From April 2017 to August 2020, patients diagnosed with aPRCA at Peking Union Medical College Hospital who were refractory/recurrent/in...

How I manage acquired pure red cell aplasia in adults.
Blood Gurnari C, Maciejewski JP

Mar 4th, 2021 - Pure red cell aplasia (PRCA) is a rare hematological disorder with multiple etiologies. The multifaceted nature of this disease is emphasized by the variety of concomitant clinical features. Classic idiopathic presentation aside, prompt recognitio...

Eltrombopag restores erythropoiesis in refractory adult acquired pure red cell aplasia.
International Journal of Hematology; Liu X, Cheng L et. al.

Feb 22nd, 2021 - Acquired pure red cell aplasia is a rare condition characterized by normocytic normochromic anemia with severe reticulocytopenia. In refractory acquired pure red cell aplasia, the low response rate of immunosuppressive therapy also constitutes a c...

see more →

Clinicaltrials.gov  1 results

Bortezomib Plus Dexamethasone for Acquired Pure Red Cell Aplasia Failure or Relapse After First-line Treatment

Sep 16th, 2020 - This is an open-label, single-arm study to evaluate the safety and efficacy of bortezomib plus dexamethasone for acquired pure red cell aplasia failure or relapse after first-line treatment.

see more →